Tempus Small Cell Lung Cancer Observational Study (Sculptor): A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays
Tempus AI
Summary
The study is a non-interventional evaluation of participants with extensive stage (ES) SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA and CTC biomarker profiling during standard of care therapy in both first and second line treatment.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
The following are the inclusion criteria. Participants are eligible to be included in this study only if all the following criteria apply. The participant has/is: 1. Histologically confirmed small cell lung cancer diagnosis 2. Diagnosis made with excisional or core needle biopsy specimen (fine needle aspirate may be permitted with approval from the Medical Monitor) 3. Subjects must submit tumor sample per the laboratory manual, defined as follows: 1L Cohort - Tissue obtained prior to the initiation of 1L therapy; 2L Cohort - Tissue obtained prior to the initiation of 1L therapy and/or a stand…
Interventions
- OtherObservation
No intervention
Locations (11)
- Cancer and Blood Specialty ClinicLos Alamitos, California
- University of ColoradoAurora, Colorado
- Illinois Cancer CarePeoria, Illinois
- Johns Hopkins UniversityBaltimore, Maryland
- Englewood Health Medical CenterEnglewood, New Jersey
- University of North CarolinaChapel Hill, North Carolina